Skip to content
AwardedUnited KingdomServices£1,677,290

Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1)

Published
Published 27 August 2025
Deadline
Closed 31 March 2025

Overview

Newborn Blood Spot screening (NBS) is a national programme offered to all babies born in the UK, and it currently screens for 9 rare but potentially lethal conditions. The blood spot screening sample is taken from the baby's heel collected on a filter paper dried blood spot (DBS) card. The blood sample is analysed by one of 13 newborn screening laboratories in England

Key details

Country
United Kingdom
Status
Awarded
Category
Services
Estimated value
£1,677,290
Procedure
Selective
SME suitable
No
Published
27 August 2025
Deadline
Closed
Classification (CPV)
Blood-testing reagents

Award outcome

Awarded value
£1,677,290
Award date
30 March 2025
Contract period
31 March 2025 → 31 March 2027
Winner
  • Revvity (UK) Limited

Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.

Notice history

Every published notice in this contracting process, newest first.

  1. Contract Award Notice

    27 August 2025

Contracting authority

  • NHS England

    Buyer

    Leeds, United Kingdom

Get the full picture

AI analysis, bid scoring, and expert strategy for this tender

Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.

See which competitors are winning the contracts you're chasing.

15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.

Awarded: Commercial Kit for screening for hereditary tyrosinemia type 1 (HT1) — won by Revvity (UK) Limited — Skim